Turn Biotechnologies Appoints 25-Year Biotech Industry Veteran Richard Peterson as Chief Financial Officer

A seasoned leader has a proven track record of working with global investors to raise billions of dollars

MOUNTAIN VIEW, Calif., November 2, 2022 /PRNewswire/ — Turn Biotechnologies, a cellular rejuvenation company developing new mRNA-based drugs to treat incurable age-related conditions, today announced the appointment of Richard “Ric” Peterson as Director financial.

Mr. Peterson, who has served as CFO of numerous public and private biotechnology and pharmaceutical companies, has extensive experience in private financing, public offerings and complex global transactions. He will oversee all financial functions and fundraising efforts as Turn Bio prepares to launch its clinical programs.

“Ric’s experience with biotech companies at various stages of development and his experience as a financial and business executive will be great assets as Turn Bio enters the next phases of growth,” said the CEO of the company. company. Anja Kramer. “As Turn Bio moves towards the clinic, Ric will strengthen our team’s expertise and help communicate our unique vision for treating the diseases of aging within the investment community.”

During his 25 years as CFO, Peterson led traditional fundraising efforts for preclinical, clinical, and commercial companies, managed IPOs, and oversaw corporate buys and sells. He has completed more than 40 transactions representing billions of dollars.

“I am delighted to join the Turn Bio team at this important milestone, when the potential for growth and value creation in the business is exceptional,” said Peterson. “The talented team of cell rejuvenation executives and pioneers have successfully brought Turn Bio to this stage, achieved breakthroughs in epigenetic reprogramming, and developed a revolutionary delivery system that overcomes the main obstacle to cell therapies. I have looking forward to helping lead the next stage of our growth.”

Peterson has worked with several clinical-stage biopharmaceutical companies, including Clarus Therapeutics, Sienna Biopharmaceuticals, Dermavant Sciences Inc. and Novan Inc. He also served as Chief Financial Officer of Medicis Pharmaceutical Corporation, a commercial pharmaceutical company. Under Peterson’s leadership, Novan and Sienna had successful IPOs. At Medicis, he helped lead the company’s growth, which culminated in its $2.6 billion acquisition by Valeant Pharmaceuticals International.

Peterson is a director of Universal Insurance Holdings, where he chairs the audit committee of the board.


Turn Bio is a preclinical-stage company focused on cellular-level tissue repair and the development of transformative drug delivery systems. The company’s proprietary mRNA platform technology, ERA™, restores optimal gene expression by combating the effects of aging in the epigenome. This restores the ability of cells to prevent or treat disease and to heal or regenerate tissue. It will help in the fight against incurable chronic diseases. Its eTurna™ delivery platform uses unique formulations to precisely deliver cargo to specific organs, tissues and cell types.

The company completes preclinical research on tailored therapies targeting indications in dermatology and immunology, and develops therapies for ophthalmology, osteoarthritis and the muscular system. For more information, visit www.turn.bio.


Jim Martinezrights history group
[email protected] or (312) 543-9026

Photo – https://mma.prnewswire.com/media/1935041/Turn_Biotechnologies_Ric_Peterson.jpg
Logo – https://mma.prnewswire.com/media/1935529/TURN_LOGO_HI_RES_Logo.jpg

SOURCETurn Biotechnologies, Inc.

Previous Governor Newsom announces appointments 11.1.22
Next IDENTOS Expands Digital Access Capability for MEDITECH's Expanse Patient Portal